Last $0.11 USD
Change Today +0.025 / 29.41%
Volume 35.1K
IMMD On Other Exchanges
Symbol
Exchange
OTC US
As of 5:20 PM 08/28/14 All times are local (Market data is delayed by at least 15 minutes).

immudyne inc (IMMD) Snapshot

Open
$0.09
Previous Close
$0.09
Day High
$0.11
Day Low
$0.09
52 Week High
12/6/13 - $0.41
52 Week Low
07/24/14 - $0.08
Market Cap
3.2M
Average Volume 10 Days
4.9K
EPS TTM
--
Shares Outstanding
29.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IMMUDYNE INC (IMMD)

Related News

No related news articles were found.

immudyne inc (IMMD) Related Businessweek News

No Related Businessweek News Found

immudyne inc (IMMD) Details

Immudyne, Inc. engages in the development, manufacture, and sale of natural immune support products primarily in the United States. It offers nutraceutical and cosmetic product lines that consist of yeast beta glucans in oral and topical applications. The company‘s nutraceutical and cosmetic products for yeast beta glucans are the MacroForce Plus, once-daily oral capsule; and Skin Care Essentials line of rejuvenating serums and creams. Immudyne, Inc. sells its products directly to consumers; and to pharmaceutical, nutraceutical, and consumer product companies through healthcare professionals and distributors. The company was incorporated in 1987 and is based in Mount Kisco, New York.

3 Employees
Last Reported Date: 03/28/14
Founded in 1987

immudyne inc (IMMD) Top Compensated Officers

Chief Executive Officer, President, Principal...
Total Annual Compensation: $145.6K
Compensation as of Fiscal Year 2013.

immudyne inc (IMMD) Key Developments

ImmuDyne, Inc. expected to report Q2 2014 results on August 16, 2014. This event was calculated by Capital IQ (Created on August 9, 2014).

ImmuDyne, Inc. expected to report Q2 2014 results on August 16, 2014. This event was calculated by Capital IQ (Created on August 9, 2014).

ImmuDyne, Inc. and Adiuvo Investment S.A. Forms Strategic Joint Venture

ImmuDyne, Inc. and Adiuvo Investment S.A. announced the signing of a memorandum of understanding (MOU) to form a strategic joint venture on all non-US business to anticipate the filing of new patents. ImmuDyne and Adiuvo will each own 50% of the JV, with the option for Adiuvo to purchase up to a 10% interest in ImmuDyne within the next nine months. ImmuDyne will also be given the option of acquiring the same interest in Adiuvo. The JV is anticipated to launch in the first quarter of 2014. The JV will initially consist of several oral and topical finished products that enhance immune response.

ImmuDyne, Inc. Adds $1.25 Million of Retail Inventory of its New Dietary Supplements; iNR Wellness, iNR Wellness MD, and iNR Strength

ImmuDyne, Inc. announced that it has added inventory for the launch of its new dietary supplement lines for sale; iNR Wellness(TM), iNR Wellness MD(TM), and iNR Strength(TM), with a retail value of over $1.25 million. The products will be promoted through physician networks, fitness experts, online advertising, test-market television sponsorships, and social media. The products will be available to consumers through an online store this October and the campaigns will launch later in 2013. iNR Wellness, iNR Wellness MD, and iNR Strength all contain the active ingredient PURACERE(TM). PURACERE is a proprietary, clinically researched, doctor- recommended, yeast beta 1,3/1,6-D-glucan. PURACERE is the purist yeast beta-glucan available. Unlike many other immune support dietary supplements, PURACERE does not contain any yeast by-products, endotoxins, excessive proteins, or ash. PURACERE has been clinically proven to prime the immune system and support immune health.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMMD:US $0.11 USD +0.025

IMMD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IMMD.
View Industry Companies
 

Industry Analysis

IMMD

Industry Average

Valuation IMMD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.0x
Price/Book 176.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUDYNE INC, please visit www.immudyne.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.